Patents by Inventor Stephen Wright

Stephen Wright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11404254
    Abstract: An ion source with an insertable target holder for holding a solid dopant material is disclosed. The insertable target holder includes a pocket or cavity into which the solid dopant material is disposed. When the solid dopant material melts, it remains contained within the pocket, thus not damaging or degrading the arc chamber. Additionally, the target holder can be moved from one or more positions where the pocket is at least partially in the arc chamber to one or more positions where the pocket is entirely outside the arc chamber. In certain embodiments, a sleeve may be used to cover at least a portion of the open top of the pocket.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: August 2, 2022
    Assignee: Varian Semiconductor Equipment Associates, Inc.
    Inventors: Shreyansh Patel, Graham Wright, Daniel Alvarado, Klaus Becker, Daniel R. Tieger, Stephen Krause
  • Patent number: 11400055
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). In particular the TSC is treatment resistant and is characterised by generalised seizures or focal seizures with impairment. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: June 7, 2021
    Date of Patent: August 2, 2022
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Elizabeth Thiele
  • Publication number: 20220219109
    Abstract: Provided are apparatus and systems for performing a swing adsorption process. This swing adsorption process may involve performing dampening for fluctuations in the streams conducted away from the adsorbent bed unit. The process may be utilized for swing adsorption processes, such as rapid cycle TSA and/or rapid cycle PSA, which are utilized to remove one or more contaminants from a gaseous feed stream.
    Type: Application
    Filed: March 29, 2022
    Publication date: July 14, 2022
    Inventors: Ananda K. Nagavarapu, Stephen Wright, Bennett D. Marshall, Brett L. Ryberg
  • Publication number: 20220202738
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: March 8, 2022
    Publication date: June 30, 2022
    Inventors: Geoffrey GUY, Stephen WRIGHT, Orrin DEVINSKY
  • Patent number: 11357741
    Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: June 14, 2022
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Publication number: 20220169668
    Abstract: The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat neurocognitive disorders (e.g., Alzheimer's disease, Parkinson's disease), ADHD, Epilepsy, Autism, Sleep-wake disorders, Chronic pain, Inflammatory Disorders, IBD, Stroke, ALS, and/or Multiple Sclerosis.
    Type: Application
    Filed: April 17, 2020
    Publication date: June 2, 2022
    Inventors: Derek John LONDESBROUGH, Christopher BROWN, Julian Scott NORTHEN, Gillian MOORE, Hemant Kashinath PATIL, David E. NICHOLS, Megan CROAL, Hans Ake ERIKSSON, George GOLDSMITH, Molly Tabitha HICKEY, Shaun HURLEY, Ekaterina MALIEVSKAIA, Lindsey MARWOOD, Drummond E-Wen Joe MCCULLOCH, Laurie Emma MEDHURST, Nathan POULSEN, Aslihan SELIMBEYOGLU, Anais SOULA, Amanda Tan SHUXIANG, Manon Cecile Elisabeth VERAART, Tobias Patrick WHELAN, Lars Christian WILDE, Stephen WRIGHT
  • Patent number: 11331620
    Abstract: Provided are apparatus and systems for performing a swing adsorption process. This swing adsorption process may involve performing dampening for fluctuations in the streams conducted away from the adsorbent bed unit. The process may be utilized for swing adsorption processes, such as rapid cycle TSA and/or rapid cycle PSA, which are utilized to remove one or more contaminants from a gaseous feed stream.
    Type: Grant
    Filed: January 21, 2019
    Date of Patent: May 17, 2022
    Assignee: ExxonMobil Upstream Research Company
    Inventors: Ananda Krishna Nagavarapu, Bennett D. Marshall, Brett L. Ryberg, Stephen Wright
  • Patent number: 11326834
    Abstract: A method of operating, during an at least partial shutdown of a refrigerant distribution subsystem in a natural gas liquefaction facility, can include: draining down at least a portion of a mixed refrigerant in one or more components of the refrigerant distribution subsystem into a high-pressure holding tank of a drain down subsystem, wherein draining down to the high-pressure holding tank is achieved by pumping the mixed refrigerant from the refrigerant distribution subsystem to the high-pressure holding tank or backfilling the refrigerant distribution subsystem with a backfill gas; and optionally, transferring at least a portion of the mixed refrigerant into a low-pressure drum from the high-pressure holding tank.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: May 10, 2022
    Assignee: ExxonMobil Upstream Research Company
    Inventors: Brett L. Ryberg, Stephen Wright, Kenichi Tadano, Naoki Watanabe
  • Patent number: 11311498
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: April 26, 2022
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Publication number: 20220096397
    Abstract: The present invention relates to parenteral cannabinoid formulations, and more particularly to cannabinoid containing intravenous (IV) formulations. Preferably the parenteral containing formulation comprises a cannabinoid; an isotonic agent; a surfactant; and one or more stability enhancers. Furthermore the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerol propyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).
    Type: Application
    Filed: December 10, 2021
    Publication date: March 31, 2022
    Inventors: Stephen WRIGHT, Jitinder Wilkhu
  • Publication number: 20220088041
    Abstract: The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.
    Type: Application
    Filed: December 2, 2021
    Publication date: March 24, 2022
    Applicant: COMPASS PATHFINDER LIMITED
    Inventors: Derek John LONDESBROUGH, Christopher BROWN, Julian Scott NORTHEN, Gillian MOORE, Hemant Kashinath PATIL, David E. NICHOLS, Megan CROAL, Hans Åke ERIKSSON, George GOLDSMITH, Molly Tabitha HICKEY, Shaun HURLEY, Ekaterina MALIEVSKAIA, Lindsey MARWOOD, Drummond E-Wen Joe MCCULLOCH, Laurie Emma MEDHURST, Nathan POULSEN, Aslihan SELIMBEYOGLU, Anaïs SOULA, Amanda Tan SHUXIANG, Manon Cecile Elisabeth VERAART, Tobias Patrick WHELAN, Lars Christian WILDE, Stephen WRIGHT
  • Publication number: 20220057290
    Abstract: A flexible lid seal detector incorporates a compression body having a cavity including a sensor. The detector has a distal end comprising a plurality of concentric compression rings surrounding the cavity. An outer-most ring is defined by outer and inner shaping rims. The distal end includes a recessed lid deflection volume defined by the inner rim and a distal surface of the compression body. The deflection volume may receive a portion of a flexible lid when at least one of the rings applies a compressive force thereto, thereby deforming the lid into the deflection volume. The deflection volume may include a second compression ring and its respective inner and outer shaping rims. A seal detector system may include the detector with a controller configured to receive data from the sensor for a predetermined period of time while the detector applies the compressive force to the lid.
    Type: Application
    Filed: August 21, 2020
    Publication date: February 24, 2022
    Inventors: Eric E. Meade, Stephen Wright
  • Patent number: 11229612
    Abstract: The present invention relates to parenteral cannabinoid formulations, and more particularly to cannabinoid containing intravenous (IV) formulations. Preferably the parenteral containing formulation comprises a cannabinoid; an isotonic agent; a surfactant; and one or more stability enhancers. Furthermore the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerolpropyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: January 25, 2022
    Assignee: GW Research Limited
    Inventors: Stephen Wright, Jitinder Wilkhu
  • Publication number: 20220000800
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: September 16, 2021
    Publication date: January 6, 2022
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Publication number: 20210401771
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: September 10, 2021
    Publication date: December 30, 2021
    Inventors: Geoffrey GUY, Stephen WRIGHT, Orrin DEVINSKY
  • Publication number: 20210379132
    Abstract: This disclosure describes a composition including the ginsenoside 20(S)-Rg3 (also referred to herein as Rg3) and methods of using such a composition. In some embodiments, the composition may be used to treat or prevent an alpha herpesvirus including, for example, herpes simplex virus (HSV)-1 and HSV-2. In some embodiments, the composition is substantially free of other ginsenosides.
    Type: Application
    Filed: June 4, 2021
    Publication date: December 9, 2021
    Inventors: Stephen Wright, Shannon Smith, Karen Maynard, Elliot Altman
  • Publication number: 20210330636
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Lennox-Gastaut syndrome; Dravet syndrome; or Acardi syndrome.
    Type: Application
    Filed: July 21, 2020
    Publication date: October 28, 2021
    Inventors: Geoffrey GUY, Stephen WRIGHT, Orrin DEVINSKY
  • Patent number: 11154516
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: October 26, 2021
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 11154517
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: October 26, 2021
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Publication number: 20210308072
    Abstract: The present invention relates to the use of a combination of two different cannabinoids in the treatment of leukaemia. The combination of CBD with THC appears to be particularly effective in reducing cell number in this disease. Preferably the cannabinoids are used in the form of an extract of cannabis such that many of the naturally occurring compounds are co-extracted with the THC or CBD. Alternatively, the cannabinoids are present in the form of a highly purified extract of cannabis, wherein the CBD or THC are present at greater than 98% of the total extract (w/w) and the other components of the extract are characterized. Alternatively, the CBD and THC may be synthetically produced. A specific ratio of CBD and THC such as 10:1 to 1:10 (CBD:THC) or more preferably between 2:1 to 1:2 (CBD:THC) may be used.
    Type: Application
    Filed: April 15, 2021
    Publication date: October 7, 2021
    Applicant: GW Research Limited
    Inventors: Stephen Wright, Wai Liu, Katherine Scott, Angus Dalgleish